Provident Financial Services: Akeso's Ivonescimab Revolutionizes Lung Cancer Treatment in China
- Akeso, Inc. received NMPA approval for ivonescimab, enhancing treatment options for advanced non-small cell lung cancer in China.
- The updated label shows significant improvements in survival rates, with reduced risks of death and disease progression.
- Ivonescimab was added to China's National Reimbursement Drug List, increasing patient access to this innovative therapy.
Innovative Cancer Treatment Gains Traction in China
Akeso, Inc. has recently achieved a significant milestone with the approval from the National Medical Products Administration (NMPA) in China for an updated label for ivonescimab, a PD-1/VEGF bispecific antibody. This label update, which stems from the final analysis of the pivotal AK112-301/HARMONi-A study, highlights substantial advancements in treatment outcomes for patients suffering from locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) who have previously progressed after receiving EGFR-TKI therapy. The HARMONi-A trial stands out as the first Phase III immunotherapy study to report notable improvements in both progression-free survival (PFS) and overall survival (OS) among this specific patient population.
The final OS analysis, based on a median follow-up period of 32.5 months, reveals that the combination therapy with ivonescimab reduces the risk of death by 26%, with a hazard ratio of 0.74 (P=0.019). Additionally, it demonstrates a remarkable 54% reduction in the risk of disease progression or death (PFS HR=0.46, P＜0.001), extending the median PFS from 4.8 months to 7.1 months. The long-term safety profile of ivonescimab remains favorable, with no new safety signals reported, which is critical for gaining the trust of healthcare providers and patients alike. This update is expected to enhance the accessibility of ivonescimab for patients in need of effective treatment options for nsq-NSCLC.
Originally approved for this indication in May 2024, ivonescimab has already been included in China's National Reimbursement Drug List (NRDL) as of November 2024, effective January 1, 2025. This inclusion ensures that a larger patient population can access this innovative therapy. Furthermore, the treatment was approved for first-line use in PD-L1-positive NSCLC in April 2025 and subsequently added to the NRDL in early 2026. This progression indicates a growing recognition of ivonescimab as a highly effective, well-tolerated, and durable chemotherapy-free option for lung cancer treatment in China.
In conclusion, the label update for ivonescimab marks a pivotal development in the treatment landscape for nsq-NSCLC, particularly for patients who have exhausted other therapeutic options. The favorable outcomes from the HARMONi-A study position ivonescimab as a leading choice in immunotherapy, reflecting a broader trend in the industry towards innovative and effective cancer treatments. As Akeso continues to expand the availability of this therapy, it underscores the importance of ongoing clinical research and the regulatory support that facilitates access to groundbreaking medical advancements.